A Reversal for Kala Pharmaceuticals, Inc. (KALA) Is Not Near. The Stock Reaches All-Time Low Today

The stock of Kala Pharmaceuticals, Inc. (NASDAQ:KALA) reached all time low today, Aug, 15 and still has $3.78 target or 6.00 % below today’s $4.02 share price. This indicates more downside for the $136.71M company. This technical setup was reported by Barchart.com. If the $3.78 PT is reached, the company will be worth $8.20 million less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only.

The stock decreased 8.01% or $0.35 during the last trading session, reaching $4.02. About 576,625 shares traded or 117.13% up from the average. Kala Pharmaceuticals, Inc. (NASDAQ:KALA) has declined 51.96% since August 15, 2018 and is downtrending. It has underperformed by 51.96% the S&P500.

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Ratings Coverage

Among 2 analysts covering Kala Pharmaceuticals (NASDAQ:KALA), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Kala Pharmaceuticals has $15 highest and $1200 lowest target. $13.50’s average target is 235.82% above currents $4.02 stock price. Kala Pharmaceuticals had 7 analyst reports since February 25, 2019 according to SRatingsIntel. The rating was maintained by H.C. Wainwright with “Buy” on Wednesday, August 7.

More notable recent Kala Pharmaceuticals, Inc. (NASDAQ:KALA) news were published by: Benzinga.com which released: “90 Biggest Movers From Friday – Benzinga” on August 12, 2019, also Seekingalpha.com with their article: “DelMar Pharmaceuticals leads healthcare gainers; Lexicon Pharmaceuticals and T2 Biosystems among losers – Seeking Alpha” published on July 31, 2019, Nasdaq.com published: “Kala Pharmaceuticals Reports Disappointing Q2 Sales – Nasdaq” on August 06, 2019. More interesting news about Kala Pharmaceuticals, Inc. (NASDAQ:KALA) were released by: Benzinga.com and their article: “The Daily Biotech Pulse: Sanofi’s Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering – Benzinga” published on August 06, 2019 as well as Benzinga.com‘s news article titled: “50 Healthcare Stocks Moving In Thursday’s After-Market Session – Benzinga” with publication date: August 09, 2019.

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle Mucus Penetrating Particles technology. The company has market cap of $136.71 million. The companyÂ’s product candidates include KPI-121 1.0%, which has completed Phase 3 clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-121 0.25% that is in Phase 3 clinical trials for the temporary relief of the signs and symptoms of dry eye disease. It currently has negative earnings. It also develops KPI-285, a receptor kinase inhibitor, which is in preclinical studies for the treatment of various retinal diseases.

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.